As far as some synthetic agonists of GPR55 were recently described to induce cell death in breast cancer cells [37], it could be worthwhile testing whether the LPI cytotoxicity enhancement also takes place for other GPR55 ligands or is specific to the NADA class. Here, GPR55 is linked to breast cancer.